WuXi AppTec's Chemistry Segment Strength May Offset Weakness Elsewhere -- Market Talk

Dow Jones10-25

0325 GMT - WuXi AppTec may report a 6% on-year rise in 3Q sales, excluding the impact of Covid projects, Nomura analyst Jialin Zhang says in a research note. Likely stronger revenue growth for WuXi's chemistry segment could offset softening growth of other segments, Zhang says. The status of the Biosecure bill will be closely monitored after the U.S. presidential election, Zhang says. If the company disposes of U.S.-based gene and cell therapy unit WuXi ATU, "we believe it will potentially be less exposed to geopolitical risks," he adds. Nomura maintains its buy rating on WuXi and raises its target price to HK$63.12 from HK$43.45 on a recent improvement in sentiment. WuXi AppTec's H-shares are 4.5% higher at HK$52.20. (sherry.qin@wsj.com)

(END) Dow Jones Newswires

October 24, 2024 23:25 ET (03:25 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478642461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-25 11:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478642461","market":"us","top_or_hot":-1,"title":"WuXi AppTec's Chemistry Segment Strength May Offset Weakness Elsewhere -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0325 GMT - WuXi AppTec may report a 6% on-year rise in 3Q sales, excluding the impact of Covid projects, Nomura analyst Jialin Zhang says in a research note. Likely stronger revenue growth for WuXi's chemistry segment could offset softening growth of other segments, Zhang says. The status of the Biosecure bill will be closely monitored after the U.S. presidential election, Zhang says. If the company disposes of U.S.-based gene and cell therapy unit WuXi ATU, \"we believe it will potentially be less exposed to geopolitical risks,\" he adds. Nomura maintains its buy rating on WuXi and raises its target price to HK$63.12 from HK$43.45 on a recent improvement in sentiment. WuXi AppTec's H-shares are 4.5% higher at HK$52.20. (sherry.qin@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2024 23:25 ET (03:25 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi AppTec's Chemistry Segment Strength May Offset Weakness Elsewhere -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi AppTec's Chemistry Segment Strength May Offset Weakness Elsewhere -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 11:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0325 GMT - WuXi AppTec may report a 6% on-year rise in 3Q sales, excluding the impact of Covid projects, Nomura analyst Jialin Zhang says in a research note. Likely stronger revenue growth for WuXi's ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2478642461","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478642461","pubTimestamp":1729826700,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0325 GMT - WuXi AppTec may report a 6% on-year rise in 3Q sales, excluding the impact of Covid projects, Nomura analyst Jialin Zhang says in a research note. Likely stronger revenue growth for WuXi's chemistry segment could offset softening growth of other segments, Zhang says. The status of the Biosecure bill will be closely monitored after the U.S. presidential election, Zhang says. If the company disposes of U.S.-based gene and cell therapy unit WuXi ATU, \"we believe it will potentially be less exposed to geopolitical risks,\" he adds. Nomura maintains its buy rating on WuXi and raises its target price to HK$63.12 from HK$43.45 on a recent improvement in sentiment. WuXi AppTec's H-shares are 4.5% higher at HK$52.20. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BK0216":"研究试验","LU1997245177.USD":"安联神洲A股基金"},"translate_title":"药明康德化学领域的实力可能会抵消其他领域的疲软——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9},"content_text":"0325 GMT - WuXi AppTec may report a 6% on-year rise in 3Q sales, excluding the impact of Covid projects, Nomura analyst Jialin Zhang says in a research note. Likely stronger revenue growth for WuXi's chemistry segment could offset softening growth of other segments, Zhang says. The status of the Biosecure bill will be closely monitored after the U.S. presidential election, Zhang says. If the company disposes of U.S.-based gene and cell therapy unit WuXi ATU, \"we believe it will potentially be less exposed to geopolitical risks,\" he adds. Nomura maintains its buy rating on WuXi and raises its target price to HK$63.12 from HK$43.45 on a recent improvement in sentiment. WuXi AppTec's H-shares are 4.5% higher at HK$52.20. (sherry.qin@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 24, 2024 23:25 ET (03:25 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478642461"}